IXICO PLC (AIM:IXI, FRA:PYPB, OTC:PHYOF) said it landed a deal worth in excess of US$750,000 over two years to supply advanced neuroimaging services to an unnamed top-five global clinical research organisation (CRO) to support a phase II Alzheimer’s trial.
The study, which will be conducted at 41 sites in the US and Europe, will assess the safety and efficacy of an injected drug treating sufferers with mild and moderate symptoms.
Chief executive Giulio Cerroni said: “One of the core elements of our commercial growth strategy has been to establish strong relationships with select therapeutically aligned partner CROs.
“This enables greater access to new biopharmaceutical clients and accelerates the adoption of our proprietary neuroimaging technology solutions, at scale.”